Jul. 15 at 5:29 PM
A blood-cancer diagnostics market worth roughly
$500 million in the US sits largely untapped, and Precipio, Inc. (Nasdaq:
$PRPO ) intends to scale into it without much added cost. Danieli used his Planet MicroCap Las Vegas 2026 slot to map the runway, from current production capacity to a long-term shift in the company's revenue mix.
Precipio, Inc. - Nasdaq: PRPO is a B2i Digital Featured Company. See the company's profile at b2idigital.com/precipio-inc-1 and follow Precipio on X, LinkedIn, and Facebook.
"On the product side, we currently have capacity to produce about
$50 million of product annually," said Danieli. "We did three last year, so plenty of room to grow with no further investment. And if we had to go beyond that, if we had to double that capacity, it's about
$700,000 to double our capacity from 50 million to 100 million. So extremely scalable in our business."
Beyond the numbers, Danieli walked through:
• A blood-cancer diagnostics market of roughly
$500 million in the US, with Precipio's tests covering about 85% of blood cancer diseases
• A planned shift in revenue mix from about 90% laboratory services and 10% products today toward 60/40, with products carrying roughly 80% margins
• Longer-term plans to extend the same model into solid tumors and molecular tests beyond cancer
Watch the full presentation: https://youtu.be/xX88-sWtszM
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the problem of cancer misdiagnoses by developing diagnostic products and services designed to deliver greater accuracy, improved laboratory workflow, and better patient outcomes. Precipio develops, validates, and clinically uses these technologies in its laboratory before commercializing them as proprietary products for the global laboratory community. More information is at precipiodx.com. Investor inquiries:
[email protected], +1-203-787-7888 Ext. 523.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: This post is informational only and is not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser.
$EXAS,
$NTRA,
$GH,
$XBI